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Monkeypox virus (MPV) belongs to the orthopoxvirus genus of the family Poxviridae, is endemic in parts of Africa, and
causes a human disease that resembles smallpox. The 196,858-bp MPV genome was analyzed with regard to structural
features and open reading frames. Each end of the genome contains an identical but oppositely oriented 6379-bp terminal
inverted repetition, which similar to that of other orthopoxviruses, includes a putative telomere resolution sequence and short
tandem repeats. Computer-assisted analysis was used to identify 190 open reading frames containing 60 amino acid
residues. Of these, four were present within the inverted terminal repetition. MPV contained the known essential orthopox-
virus genes but only a subset of the putative immunomodulatory and host range genes. Sequence comparisons confirmedINTRODUCTION
The family Poxviridae consists of complex double-
stranded DNA viruses that are distinguished by their
replication in the cytoplasm of vertebrate or invertebrate
cells (Moss, 2001). Poxviruses belonging to the orthopox-
virus genus include the closely related variola (VAR),
monkeypox (MPV), cowpox (CPV), and vaccinia (VAC)
viruses (Fenner et al., 1989; Marennikova and Shchel-
kunov, 1998). VAR is the etiologic agent of human small-
pox, an epidemic disease with mortality rates of 10–40%
that was eliminated by a strategy of case identification
and prophylactic vaccination of contacts with live VAC
through the coordinated efforts of the world community
under the aegis of the World Health Organization (Fenner
et al., 1988). Following smallpox eradication in 1977,
vaccination ceased, resulting in a decline in immunity to
other orthopoxviruses as well as VAR. Thus, there is now
increased susceptibility to zoonotic orthopoxviruses in-
cluding MPV, CPV, and strains of VAC (Damaso et al.,
2000; Esposito and Fenner, 2001). Potentially, increased
circulation of these viruses in the human population
could lead to adaptive increases in their pathogenicity or
transmissibility. MPV is of greatest concern because
human monkeypox, a sporadic disease in the tropical
rainforest regions of Central and Western Africa, is sim-0042-6822/02
172ilar to smallpox in its clinical manifestations and appears
to be increasing in frequency (Breman, 2000; Hutin et al.,
2001; Jezek and Fenner, 1988; Marennikova et al., 1972;
Mukinda et al., 1997).
The similar clinical manifestation of monkeypox and
smallpox led to a hypothesis that MPV is the evolutionary
ancestor of VAR (Fenner, 1977; Marennikova et al., 1972;
Noble, 1970). Comparisons of VAR and MPV, based on
genomic restriction endonuclease maps (Esposito and
Knight, 1985; Mackett and Archard, 1979) or nucleotide
sequences of individual viral genes (Douglass and Dum-
bell, 1992; Esposito and Knight, 1984; Hutin et al., 2001;
Mukinda et al., 1997), were interpreted by some as indi-
cating that MPV and VAR evolved independently (Doug-
lass and Dumbell, 1992) and by others that VAR is an-
cestral to MPV (Bugert and Darai, 2000). Because a
reliable answer to this question could be obtained only
through comparisons of complete genomes, we se-
quenced the DNA of a recent human MPV isolate, strain
ZAI-96-I-16 (MPV-ZAI), and concluded that MPV was not
the immediate ancestor or descendent of VAR (Shchel-
kunov et al., 2001).
We carried out a detailed analysis of the 196,858-bp
MPV-ZAI DNA sequence, comprising the entire genome
with the exception of part of the covalently closed termi-
nal hairpin loops, and compared this with the corre-
sponding complete genome sequences of VAC (Antoine
et al., 1998; Goebel et al., 1990), VAR (Massung et al.,the assignment of MPV as a distinct species of orthopoxvi
virus, the causative agent of smallpox.
1 To whom correspondence and reprint requests should be ad-
dressed. E-mail: bmoss@nih.gov.
doi:10.1006/viro.2002.1446t is not a direct ancestor or a direct descendent of variola
1994; Shchelkunov et al., 1993d, 1995, 2000), and the
partial sequence of CPV (Shchelkunov et al., 1998).rus tha
RESULTS AND DISCUSSION
Genome topography
The ends of orthopoxvirus genomes contain an identical
but oppositely oriented sequence called a terminal inverted
repetition (ITR) (Garon et al., 1978; Wittek et al., 1978), which
includes a set of short tandem repeats (Wittek and Moss,
1980) and terminal hairpins (Baroudy et al., 1982). The
MPV-ZAI genome contains a 6379-bp ITR. Using S1 nucle-
ase hydrolysis and DNA polymerase I repair, we suc-
FIG. 1. Comparison of the terminal region of MPV and other orthopoxviruses. Upper line shows the sequenced part of the MPV-ZAI terminal loop.
Sequences, which are necessary for telomere resolution, are boxed. Nucleotides, which differ from VAC-WR sequence, are printed in bold font. ZAI,
BSH, and WR represent the virus strains Zaire-96-I-16, Bangladesh, and Western Reserve, respectively.
FIG. 2. Patterns of tandem repeats within the ITR region of MPV and other orthopoxviruses. White rectangles indicate unique ITR sequences: NR
I and NR II and the coding region. The black diamonds correspond to 70-bp tandem repeats with their numbers indicated above. The gray triangles
correspond to 54-bp repeats with their numbers indicated below. The pentagons in the ITR sequence of VAC-COP and VAC-WR indicate the 125-bp
repeats. The open diamonds and triangles indicate that these repeats differ from the consensus sequence by deletions, substitutions, or inserts. The
black circle denotes the terminal hairpin. Dotted lines indicate the absence of corresponding DNA.
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CPV-GRI isologs Identityd ReferencesStart Stop
J1L* 1611 871 246 E–L Secreted CC-chemokine-
binding protein
— VAR — Graham et al. (1997);
Smith et al. (1997)C23L VAC (244 aa) 86.4/242
D1L CPV (255 aa) 86.7/255
J2L* 2786 1740 348 E Secreted TNF-binding protein — VAR — Upton et al. (1991);
Shchelkunov et al.
(1993a); Hu et al. (1994)
C22L VAC (122 aa) 83.5/91
D2L CPV (351 aa) 90.3/351
J3L* 4640 2877 587 Ankyrin-like — VAR — Shchelkunov et al. (1993b);
Safronov et al. (1996)C21L VAC (113 aa) 96.9/97
C20L VAC (103 aa) 69.6/115
C19L VAC (259 aa) 83.2/232
D3L CPV (586 aa) 96.6/586




C1L CPV (437 aa) 97.5/437
D2L 7121 6927 64 VAC C7L-like D1.5L VAR (128 aa) 89.2/65 Shchellkunov et al. (1998)
— VAC —
C4L CPV (170 aa) 95.4/65
D3R 7556 7984 142 E Secreted EGF-like growth
factor
D2R VAR (140 aa) 86.3/139 Blomquist et al. (1984);
Buller et al. (1988)C11R VAC (142 aa) 91.5/141
C5R CPV (138 aa) 91.3/138
D4L 9081 8830 83 E D3L VAR (330 aa) 94.0/83 Venkatesan et al. (1982)
C10L VAC (331 aa) 95.2/83
C6L CPV (331 aa) 96.4/83
D5R 9567 10,295 242 L Zinc binding, virulence factor,
inhibits UV-induced
apoptosis
D4R VAR (242 aa) 95.5/242 Upton et al. (1994);
Senkevich et al. (1994);
Brick et al. (2000)
— VAC —
C7R CPV (242 aa) 97.5/242
D6L 10,903 10,523 126 E Secreted IL-18-binding
protein
D5L VAR (126 aa) 92.1/126 Born et al. (2000); Smith et
al. (2000); Calderara et
al. (2001)
— VAC —
C8L CPV (124 aa) 79.7/123




C9L CPV (668 aa) 92.4/669
D8L 13,273 13,079 64 — VAR —
— VAC —
C10L CPV (62 aa) 93.8/64
D9L 15,325 13,433 630 E Ankyrin-like D6.5L VAR (91 aa) 90.1/91 Shchelkunov et al. (1993b)
D7L VAR (153 aa) 70.3/138
C9L VAC (634 aa) 86.0/634
C11L CPV (614 aa) 67.9/633
D10L 16,432 15,980 150 E Host range D8L VAR (150 aa) 96.7/150 Chen et al. (1992)
C7L VAC (150 aa) 96.0/150
C13L CPV (150 aa) 96.0/150
D11L 17,122 16,661 153 E D9L VAR (156 aa) 94.1/152 Cooper et al. (1981)
C6L VAC (151 aa) 92.0/150
C14L CPV (156 aa) 94.7/152
D12L 17,886 17,266 206 E BTB domain of kelch-like
protein
D10L VAR (134 aa) 90.0/130 Shchelkunov et al. (1998);
Cooper et al. (1981)C5L VAC (204 aa) 95.9/193
C15L CPV (205 aa) 97.0/197
D13L 18,878 17,931 315 E D11L VAR (316 aa) 92.1/316 Cooper et al. (1981)
C4L VAC (316 aa) 94.3/316
C16L CPV (315 aa) 94.3/316
D14L 19,710 19,060 216 E Secreted complement-
binding protein
D12L VAR (263 aa) 89.4/218 Kotwal and Moss (1988)
C3L VAC (263 aa) 93.1/218
C17L CPV (259 aa) 93.0/214
D15L 20,151 19,834 105 Discontinuous ORF (MPV
D15L–D18L) of kelch-like
protein
D13L VAR (201 aa) 93.8/80 Shchelkunov et al. (1998)
C2L VAC (512 aa) 97.1/105
C18L CPV (512 aa) 98.1/105







CPV-GRI isologs Identityd ReferencesStart Stop
D16L 20,438 20,205 77 D13L VAR (201 aa) 86.3/73
C2L VAC (512 aa) 97.3/73
C18L CPV (512 aa) 97.3/73
D17L 20,736 20,440 98 D13.5L VAR (79 aa) 97.6/42
C2L VAC (512 aa) 86.5/89
C18L CPV (512 aa) 87.6/89
D18L 21,142 20,819 107 — VAR —
C2L VAC (512 aa) 98.1/106
C18L CPV (512 aa) 99.1/106
D19L 22,010 21,366 214 E D14L VAR (214 aa) 92.5/214 Belle Isle et al. (1981)
C1L VAC (224 aa) 94.9/214
C19L CPV (231 aa) 95.8/214
P1L 22,409 22,056 117 E–L Secreted virulence factor P1L VAR (117 aa) 92.3/117 Kotwal and Moss (1989)
N1L VAC (117 aa) 89.7/117
P1L CPV (117 aa) 94.9/117
P2L 23,069 22,536 177 E P2L VAR (177 aa) 90.4/177 Tamin et al. (1988)
N2L VAC (175 aa) 90.3/175
P2L CPV (175 aa) 93.7/175
O1L 24,438 23,110 442 E–L Ankyrin-like O1L VAR (446 aa) 95.9/442 Tamin et al. (1988);
Shchelkunov et al.
(1993b)
M1L VAC (472 aa) 97.1/443
O1L CPV (474 aa) 95.7/443
O2L 25,170 24,508 220 E O2L VAR (220 aa) 95.5/220 Morgan and Roberts
(1984)M2L VAC (220 aa) 97.7/220
O2L CPV (163 aa) 97.5/163
C1L 26,153 25,299 284 E Host range; ankyrin-like O3L VAR (70 aa) 90.5/63 Gillard et al. (1986);
Shchelkunov et al.
(1993b)
C1L VAR (66 aa) 89.4/66
K1L VAC (284 aa) 95.8/284
M1L CPV (284 aa) 93.7/284
C2L 27,511 26,384 375 E Serine protease inhibitor-like,
SPI-3, prevents cell fusion
C2L VAR (373 aa) 92.2/374 Law and Smith (1992);
Turner et al. (2000)K2L VAC (369 aa) 92.2/374
M2L CPV (373 aa) 94.4/374
C3L 27,803 27,672 43 E IFN resistance, homolog of
eIF-2, inhibits eIF-2
phosphorylation
C3L VAR (88 aa) 78.6/42 Beattie et al. (1991);
Davies et al. (1991)K3L VAC (88 aa) 95.2/42
M3L CPV (88 aa) 97.6/42
C4L 29,133 27,859 424 Phospholipase D-like — VAR — Cao et al. (1997); Sung et
al. (1997)K4L VAC (424 aa) 98.3/424
M4L CPV (424 aa) 97.6/424
C5L 29,990 29,160 276 Lysophospholipase-like — VAR — Antoine et al. (1998)
K5L VAC (136 aa) 91.7/108
K6L VAC (81 aa) 94.9/78
M5L CPV (276 aa) 97.5/276
C6R 30,126 30,575 149 VAC B15R-like C4R VAR (149 aa) 97.3/149
K7R VAC (149 aa) 94.0/149
M6R CPV (161 aa) 97.3/149
C7L 31,278 30,619 219 C5L VAR (251 aa) 83.6/213
F1L VAC (226 aa) 83.6/226
G1L CPV (238 aa) 87.2/234
C8L 31,745 31,290 151 E Deoxyuridine triphosphatase C6L VAR (147 aa) 98.0/147 McGeoch (1990)
F2L VAC (147 aa) 98.6/147
G2L CPV (147 aa) 99.3/147
C9L 33,225 31,762 487 E Kelch-like C7L VAR (179 aa) 93.3/179 Xue and Cooley (1993);
Shchelkunov et al.
(1998)
F3L VAC (480 aa) 96.2/479
G3L CPV (485 aa) 97.3/484
C10L 34,195 33,236 319 E Ribonucleotide reductase,
small subunit, R2
C8L VAR (333 aa) 97.5/319 Slabaugh et al. (1988)
F4L VAC (319 aa) 98.4/319
G4L CPV (319 aa) 98.4/319
C11L 35,258 34,227 343 C9L VAR (348 aa) 85.1/348
F5L VAC (321 aa) 92.8/321









CPV-GRI isologs Identityd ReferencesStart Stop
C12L 35,436 35,215 73 C10L VAR (72 aa) 84.9/73
F6L VAC (74 aa) 94.4/72
G6L CPV (74 aa) 94.4/72
C13L 35,676 35,452 74 E C11L VAR (79 aa) 81.6/76 Panicali and Paoletti
(1982)F7L VAC (92 aa) 79.5/88
G7L CPV (80 aa) 93.4/76
C14L 36,022 35,828 64 C12L VAR (65 aa) 93.8/65
F8L VAC (65 aa) 96.9/65
G8L CPV (65 aa) 96.9/65
C15L 36,717 36,079 212 C13L VAR (212 aa) 97.6/212
F9L VAC (212 aa) 99.1/212
G9L CPV (212 aa) 99.1/212
C16L 38,023 36,704 439 L Serine/threonine protein
kinase 2, VPK2, regulation
of virion morphogenesis
C14L VAR (439 aa) 98.4/437 Lin and Broyles (1994);
Traktman et al. (1995);
Wang and Shuman
(1995); Betakova et al.
(1999)
F10L VAC (439 aa) 98.9/439
G10L CPV (439 aa) 99.1/439
C17L 39,110 38,046 354 E C15L VAR (354 aa) 93.5/354 Golini and Kates (1984)
F11L VAC (354 aa) 97.2/354
G11L CPV (354 aa) 97.2/354
C18L 41,061 39,154 635 E–L Actin tail formation C16L VAR (635 aa) 95.0/636 Zhang et al. (2000)
F12L VAC (635 aa) 97.2/636
G12L CPV (634 aa) 98.6/635
C19L 42,222 41,104 372 L Major envelope antigen of
EEV, wrapping of IMV to
form IEV, phospholipase
D-like
C17L VAR (372 aa) 97.3/372 Hirt et al. (1986); Baek et
al. (1997); Sung et al.
(1997); Roper and Moss
(1999)
F13L VAC (372 aa) 98.7/372
G13L CPV (372 aa) 98.7/372
C20L 42,461 42,240 73 E–L C18L VAR (73 aa) 78.1/73 Golini and Kates (1984)
F14L VAC (73 aa) 97.3/73
G14L CPV (73 aa) 98.6/73
C21L 43,209 42,733 158 E C19L VAR (161 aa) 98.0/153 Golini and Kates (1984)
F15L VAC (158 aa) 98.1/158
G15L CPV (158 aa) 98.7/158
C22L 43,911 43,216 231 E C20L VAR (231 aa) 95.2/231 Golini and Kates (1984)
F16L VAC (231 aa) 96.5/231
G16L CPV (231 aa) 97.0/231
C23R 43,973 44,278 101 L Virion core DNA-binding
phosphoprotein
C21R VAR (101 aa) 94.1/101 Kao and Bauer (1987)
F17R VAC (101 aa) 97.0/101
G17R CPV (101 aa) 96.0/101
F1L 45,714 44,275 479 E Poly(A) polymerase, catalytic
subunit
E1L VAR (479 aa) 97.7/479 Gershon et al. (1991)
E1L VAC (479 aa) 99.0/479
F1L CPV (479 aa) 99.4/479
F2L 47,924 45,711 737 E2L VAR (737 aa) 97.7/737
E2L VAC (737 aa) 98.0/737
F21 CPV (737 aa) 97.8/737




E3L VAR (190 aa) 85.6/153 Chang et al. (1992); Rivas
et al. (1998)E3L VAC (190 aa) 86.3/153
F3L CPV (190 aa) 86.3/153
F4L 49,449 48,670 259 E–L RNA polymerase, 30-kDa
subunit, intermediate stage
transcription factor, VITF-1
E4L VAR (259 aa) 96.5/259 Ahn et al. (1990a); Rosales
et al. (1994)E4L VAC (259 aa) 98.5/259
F4L CPV (259 aa) 98.1/259
F5R 50,477 52,180 567 E6R VAR (567 aa) 97.2/567
E6R VAC (567 aa) 98.9/567
F6R CPV (567 aa) 98.9/567
F6R 52,262 52,762 166 L Soluble myristylated protein E7R VAR (76 aa) 86.7/60 Martin et al. (1997)
E7R VAC (166 aa) 94.0/166
F7R CPV (166 aa) 94.6/166








CPV-GRI isologs Identityd ReferencesStart Stop
F7R 52,862 53,683 273 E8R VAR (273 aa) 97.1/273
E8R VAC (273 aa) 98.5/273
F8R CPV (273 aa) 98.5/273
F8L 56,711 53,691 1006 E DNA polymerase E9L VAR (1005 aa) 97.7/1006 Earl et al. (1986)
E9L VAC (1006 aa) 98.7/1006
F9L CPV (1006 aa) 98.6/1006
F9R 56,743 57,030 95 L Protein disulfide bond-
forming enzyme
E10R VAR (95 aa) 94.7/95 Senkevich et al. (2000)
E10R VAC (95 aa) 96.8/95
F10L 57,414 57,025 129 L Virion core protein E11L VAR (129 aa) 96.1/129 Wang and Shuman (1996)
E11L VAC (129 aa) 97.7/129
Q1L 59,398 57,401 665 E Q1L VAR (666 aa) 93.1/666
O1L VAC (666 aa) 97.4/666
Q2L 59,771 59,445 108 L Virion-associated
glutaredoxin
Q2L VAR (108 aa) 96.3/108 Ahn and Moss (1992a);
Rajagopal et al. (1995)O2L VAC (108 aa) 98.1/108
I1L 60,856 59,918 312 L Virosomal protein essential
for virus multiplication
K1L VAR (312 aa) 96.8/312 Ryazankina et al. (1993);
Schmitt and
Stunnenberg (1988)
I1L VAC (312 aa) 99.4/312
I2L 61,084 60,863 73 L K2L VAR (73 aa) 98.6/73 Schmitt and Stunnenberg
(1988)I2L VAC (73 aa) 98.6/73
I3L 61,894 61,085 269 E-I ssDNA-binding P-protein
interacts with R2 subunit of
ribonucleotide reductase
K3L VAR (269 aa) 98.1/269 Davis and Mathews
(1993); Rochester and
Traktman (1998)
I3L VAC (269 aa) 98.1/269
I4L 64,291 61,976 771 E Ribonucleotide reductase,
large subunit, R1
K4L VAR (771 aa) 97.7/771 Tengelsen et al. (1988)
I4L VAC (771 aa) 98.7/771
I5L 64,559 64,320 79 L IMV surface membrane
protein
K5L VAR (79 aa) 93.7/79 Takahashi et al. (1994)
I5L VAC (79 aa) 94.9/79
I6L 65,726 64,578 382 K6L VAR (382 aa) 97.6/382
I6L VAC (382 aa) 98.2/382
I7L 66,990 65,719 423 L Virion core protein, DNA
topoisomeras II homolog
K7L VAR (423 aa) 98.8/423 Kane and Shuman (1993)
I7L VAC (423 aa) 99.1/423
I8R 66,996 69,026 676 E–L Nucleoside triphosphate
phosphohydrolase II, NPH-
II, DNA, and RNA helicase
K8R VAR (676 aa) 96.7/676 Shuman (1992); Bayliss
and Smith (1996); Gross
and Shuman (1998)
I8R VAC (676 aa) 98.1/676
G1L 70,805 69,030 591 L Putative proteinase H1L VAR (591 aa) 97.1/591 Whitehead and Hruby
(1994)G1L VAC (591 aa) 98.5/591
G2L 71,137 70,802 111 E H2L VAR (111 aa) 95.5/111 Meis and Condit (1991)
G3L VAC (111 aa) 98.2/111
G3R 71,131 71,793 220 L H3R VAR (220 aa) 96.8/220 Meis and Condit (1991)
G2R VAC (220 aa) 98.6/220




H4L VAR (124 aa) 99.2/124 Gvakharia et al. (1996);
White et al. (2000)G4L VAC (124 aa) 99.2/124
G5R 72,140 73,444 434 E–L H5R VAR (434 aa) 96.3/434 Meis and Condit (1991)
G5R VAC (434 aa) 98.2/434
G6R 73,452 73,643 63 E–L RNA polymerase, 7-kDa
subunit
H5.5R VAR (63 aa) 96.8/63 Amegadzie et al. (1992)
— VAC —
G7R 73,643 74,140 165 H6R VAR (165 aa) 94.5/165
G6R VAC (165 aa) 93.9/165
G8L 75,220 74,105 371 Virion protein H7L VAR (371 aa) 98.4/371 Takahashi et al. (1994)
G7L VAC (371 aa) 98.7/371
G9R 75,251 76,033 260 I Late gene transcription
factor, VLTF-1
H8R VAR (260 aa) 99.6/260 Keck et al. (1990)
G8R VAC (260 aa) 100/260
G10R 76,053 77,075 340 L Myristylated protein H9R VAR (340 aa) 97.9/340 Martin et al. (1997)
G9R VAC (340 aa) 98.5/340
M1R 77,076 77,828 250 L Myristylated IMV surface
membrane protein
M1R VAR (250 aa) 99.2/250 Ravanello and Hruby
(1994)L1R VAC (250 aa) 98.8/250
M2R 77,860 78,138 92 M2R VAR (87 aa) 96.3/82









CPV-GRI isologs Identityd ReferencesStart Stop
M3L 79,148 78,114 344 M3L VAR (349 aa) 95.1/349
L3L VAC (350 aa) 96.6/350
M4R 79,173 79,928 251 L Virion core protein, ssDNA
binding, stimulation of I8R
helicase activity
M4R VAR (251 aa) 98.4/251 Yang et al. (1988); Bayliss
et al. (1996)L4R VAC (251 aa) 98.8/251
M5R 79,938 80,324 128 M5R VAR (128 aa) 99.2/128
L5R VAC (128 aa) 99.2/128
L1R 80,281 80,739 152 L1R VAR (159 aa) 97.4/152
J1R VAC (153 aa) 96.7/152
L2R 80,759 81,292 177 E Thymidine kinase L2R VAR (177 aa) 95.5/177 Weir and Moss (1983)
J2R VAC (177 aa) 96.6/177




L3R VAR (333 aa) 97.9/333 Gershon et al. (1991);
Schnierle et al. (1992)J3R VAC (333 aa) 98.8/333
L4R 82,274 82,831 185 E RNA pol 22-kDa subunit L4R VAR (185 aa) 97.8/185 Broyles and Moss (1986)
J4R VAC (185 aa) 100/185
L5L 83,292 82,891 133 L Essential for virus
multiplication
L5L VAR (133 aa) 100/133 Zajac et al. (1995)
J5L VAC (133 aa) 98.5/133
L6R 83,399 87,259 1286 E RNA pol 147-kDa subunit L6R VAR (1286 aa) 98.6/1286 Broyles and Moss (1986)
J6R VAC (1286 aa) 98.6/1286
H1L 87,771 87,256 171 L Tyrosine/serine protein
phosphatase, blocks IFN-
signal transduction
I1L VAR (171 aa) 98.8/171 Guan et al. (1991); Najarro
et al. (2001)H1L VAC (171 aa) 98.8/171
H2R 87,785 88,354 189 I2R VAR (189 aa) 100/189
H2R VAC (189 aa) 98.9/189
H3L 89,332 88,358 324 L IMV heparan-binding surface
membrane protein
I3L VAR (325 aa) 93.2/3239 Chertov et al. (1991); Lin
et al. (2000); da Fonseca
et al. (2000)
H3L VAC (324 aa) 3.8/324




I4L VAR (795 aa) 97.0/795 Ahn and Moss (1992b);
Kane and Shuman
(1992); Zhang et al.
(1994)
H4L VAC (795 aa) 98.1/795
H5R 91,905 92,546 213 E–L Virosome-associated, late
gene transcription factor,
VLTF-4, Ca2-binding motif
I5R VAR (221 aa) 92.8/222 Kovacs and Moss (1996);
Shchelkunov et al.
(1993c)
H5R VAC (203 aa) 93.9/213
H6R 92,547 93,491 314 E DNA topoisomerase I6R VAR (314 aa) 98.7/314 Shuman and Moss (1987)
H6R VAC (314 aa) 99.7/314
H7R 93,529 93,969 146 L I7R VAR (146 aa) 95.2/146 Rosel et al. (1986)
H7R VAC (146 aa) 97.3/146
E1R 94,013 96,550 845 E mRNA capping enzyme




F1R VAR (844 aa) 98.3/845 Morgan et al. (1984);
Shuman and Morham
(1990)
D1R VAC (844 aa) 98.6/845
E2L 96,949 96,509 146 E–L Virion core protein F2L VAR (146 aa) 97.9/146 Dyster and Niles (1991)
D2L VAC (146 aa) 98.6/146
E3R 96,942 97,643 233 L Virion core protein F3R VAR (237 aa) 94.9/237 Dyster and Niles (1991)
D3R VAC (237 aa) 96.6/237
E4R 97,643 98,299 218 E Uracil DNA glycosylase
required for DNA
replication
F4R VAR (218 aa) 96.8/218 Upton et al. (1993); Stuart
et al. (1993)D4R VAC (218 aa) 98.6/218




F5R VAR (785 aa) 98.5/785 Evans et al. (1995)
D5R VAC (785 aa) 99.5/785
E6R 100,728 102,641 637 L Early transcription factor,
VETF, small subunit
F6R VAR (637 aa) 99.2/637 Gershon and Moss (1990);
Broyles and Fesler (1990)D6R VAC (637 aa) 99.7/637
E7R 102,668 103,153 161 E RNA pol 18-kDa subunit F7R VAR (161 aa) 96.9/161 Ahn et al. (1990b)
D7R VAC (161 aa) 96.9/161








CPV-GRI isologs Identityd ReferencesStart Stop
E8L 104,030 103,116 304 L IMV surface membrane 32
kDa protein, binds cell
surface chondroitin sulfate,
IMV adsorption to cell
surface
F8L VAR (304 aa) 92.8/304 Niles and Seto (1988);
Maa et al. (1990); Hsiao
et al. (1999)
D8L VAC (304 aa) 94.7/304
E9R 104,072 104,713 213 E Mut-like F9R VAR (213 aa) 97.2/213 Koonin (1993); Lee-Chen
et al. (1988)D9R VAC (213 aa) 97.2/213
E10R 104,710 105,456 248 L Down regulation of gene
expression, Mut-like
F10R VAR (248 aa) 98.0/248 Shors et al. (1999); Koonin
(1993); Lee-Chen et al.
(1988)
D10R VAC (248 aa) 98.0/248





N1L VAR (631 aa) 98.1/631 Rodriguez et al. (1986);
Broyles and Moss
(1987); Christen et al.
(1998)
D11L VAC (631 aa) 98.6/631
E12L 108,250 107,387 287 E–L mRNA capping enzyme small
subunit, mRNA (guanine-
N7-)-methyl transferase
N2L VAR (287 aa) 98.6/287 Niles et al. (1989); Shuman
and Morham (1990)D12L VAC (287 aa) 99.0/287
E13L 109,936 108,281 551 L Needed for immature IMV
surface membrane
N3L VAR (551 aa) 98.9/551 Zhang and Moss (1992)
D13L VAC (551 aa) 98.9/551
A1L 110,413 109,961 150 I Late gene transcription
factor, VLTF-2
A1L VAR (150 aa) 100/150 Keck et al. (1990, 1993b)
A1L VAC (150 aa) 98.7/150
A2L 111,108 110,434 224 I Late gene transcription
factor, VLTF-3, zinc binding
A2L VAR (224 aa) 99.1/224 Keck et al. (1990, 1993a)
A2L VAC (224 aa) 99.1/224
A3L 111,338 111,105 77 A2.5L VAR (76 aa) 88.3/77
— VAC —
A4L 113,287 111,353 644 L Major virion core protein p4b A3L VAR (644 aa) 98.6/644 Rosel and Moss (1985)
A3L VAC (644 aa) 99.1/644
A5L 114,185 113,340 281 L 39-kDa immunodominant
virion core protein
A4L VAR (271 aa) 87.6/282 Maa and Esteban (1987);
Williams et al. (1999)A4L VAC (281 aa) 95.0/281
A6R 114,223 114,708 161 E–L RNA pol 22 and 21 kDa
subunits
A5R VAR (164 aa) 97.0/164 Ahn et al. (1992)
A5R VAC (164 aa) 97.6/164
A7L 115,823 114,705 372 L A6L VAR (372 aa) 98.4/372 Weinrich and Hruby (1986)
A6L VAC (372 aa) 98.7/372
A8L 117,979 115,847 710 L Early transcription factor,
VETF, large subunit,
needed for morphogenesis
A7L VAR (710 aa) 97.2/710 Gershon and Moss (1990);
Hu et al. (1998)A7L VAC (710 aa) 98.3/710
A9R 118,033 118,911 292 E Intermediate transcription
factor, VITF-3, 34-kDa
subunit
A8R VAR (288 aa) 98.3/288 Sanz and Moss (1999)
A8R VAC (288 aa) 98.6/288
A10L 119,194 118,892 100 A9L VAR (95 aa) 94.8/97
A9L VAC (99 aa) 97.0/100
A11L 121,870 119,195 891 L Major virion core protein p4a A10L VAR (892 aa) 97.5/892 Van Meir and Wittek
(1988)A10L VAC (891 aa) 97.1/891
A12R 121,885 122,841 318 A11R VAR (319 aa) 98.4/319
A11R VAC (318 aa) 99.4/318
A13L 123,415 122,843 190 L Virion core protein A12L VAR (189 aa) 98.4/190 Whitehead and Hruby
(1994)A12L VAC (192 aa) 96.9/192
A14L 123,651 123,439 70 L IMV inner and outer
membrane protein
A13L VAR (68 aa) 88.4/69 Takahashi et al. (1994);
Salmons et al. (1997)A13L VAC (70 aa) 92.8/69
A15L 124,029 123,757 90 L IMV inner membrane protein A14L VAR (90 aa) 97.8/90 Takahashi et al. (1994);
Salmons et al. (1997)A14L VAC (90 aa) 100/90
A16L 124,481 124,197 94 A15L VAR (94 aa) 96.8/94
A15L VAC (94 aa) 98.9/94
A17L 125,598 124,465 377 L Soluble myristylated protein A16L VAR (377 aa) 95.8/377 Martin et al. (1997)
A16L VAC (378 aa) 96.3/378
A18L 126,215 125,601 204 L IMV surface membrane
protein, early function in
virion morphogenesis
A17L VAR (203 aa) 97.1/204 Ichihashi et al. (1994);
Rodriguez et al. (1995);
Wolffe et al. (1996)









CPV-GRI isologs Identityd ReferencesStart Stop
A19R 126,230 127,708 492 E–L DNA helicase, postreplicative
negative transcription
elongation factor
A18R VAR (493 aa) 95.3/493 Simpson and Condit
(1995); Xiang et al.
(1998)
A18R VAC (493 aa) 96.1/493
A20L 127,922 127,689 77 A19L VAR (76 aa) 93.5/77
A19L VAC (77 aa) 96.1/77
A21L 128,270 127,923 115 A20L VAR (117 aa) 95.7/117
A21L VAC (117 aa) 97.4/117
A22R 128,269 129,549 426 E Processivity factor for viral
DNA pol
A21R VAR (426 aa) 96.7/426 Ishii and Moss (2001);
Klemperer et al. (2001)A20R VAC (426 aa) 97.4/426
A23R 129,479 130,042 187 A22R VAR (187 aa) 95.2/187
A22R VAC (176 aa) 98.8/173
A24R 130,062 131,210 382 E Intermediate transcription
factor, VITF-3, 45-kDa
subunit
A23R VAR (382 aa) 97.9/382 Sanz and Moss (1999)
A23R VAC (382 aa) 98.7/382
A25R 131,207 134,701 1164 E–L RNA pol 132-kDa subunit A24R VAR (1164 aa) 98.5/1163 Hooda-Dhingra et al.
(1990); Amegadzie et al.
(1991b)
A24R VAC (1164 aa) 98.8/1164
A26L 135,700 135,473 75 — VAR —
— VAC —
A27L 137,905 135,815 696 L N-terminal of A-type inclusion
body protein of CPV




A28L 139,513 137,951 520 L Major component of IMV
surface tubules, p4c
A29L VAR (498 aa) 89.8/520 Sarov and Joklik (1972)
A26L VAC (322 aa) 92.9/212
A27L CPV (518 aa) 95.8/520
A29L 139,896 139,564 110 L IMV surface membrane 14-
kDa fusion protein, binds
cell surface heparan
A30L VAR (110 aa) 93.6/110 Rodriguez and Esteban
(1987); Chung et al.
(1998)
A27L VAC (110 aa) 93.6/110
A28L CPV (110 aa) 95.5/110
A30L 140,337 139,897 146 A31L VAR (146 aa) 96.6/146
A28L VAC (146 aa) 95.9/146
A29L CPV (146 aa) 97.3/146
A31L 141,255 140,338 305 E RNA pol 35-kDa subunit A32L VAR (305 aa) 95.7/305 Amegadzie et al. (1991a)
A29L VAC (305 aa) 98.0/305
A30L CPV (305 aa) 98.0/305
A32L 141,451 141,218 77 A33L VAR (77 aa) 96.1/77
A30L VAC (77 aa) 96.1/77
A31L CPV (77 aa) 96.1/77
A33R 141,611 142,039 142 A34R VAR (140 aa) 95.8/142
A31R VAC (124 aa) 86.6/142
A32R CPV (145 aa) 96.6/145
A34L 142,908 142,006 300 E–L DNA packaging into virion,
NTP-binding motif A
A35L VAR (270 aa) 97.8/270 Koonin (1993); Cassetti et
al. (1998)A32L VAC (300 aa) 98.0/300
A33L CPV (300 aa) 99.0/300
A35R 142,936 143,481 181 L EEV envelope glycoprotein,
needed for formation of
actin-containing microvilli
and cell-to-cell spread
A36R VAR (184 aa) 92.8/180 Roper et al. (1996, 1998)
A33R VAC (185 aa) 96.1/180
A34R CPV (185 aa) 96.1/180
A36R 143,486 143,992 168 L EEV envelope glycoprotein,
lectin-like, required for
infectivity of EEV, formation
of actin-containing microvilli,
and cell-to-cell spread
A37R VAR (168 aa) 95.8/168 Blasco et al. (1993);
McIntosh and Smith
(1996); Wolffe et al.
(1997)
A34R VAC (168 aa) 95.2/168
A35R CPV (168 aa) 98.2/168
A37R 144,036 144,566 176 A38R VAR (60 aa) 91.7/60
A35R VAC (176 aa) 97.7/176
A36R CPV (176 aa) 98.3/176




A39R VAR (216 aa) 91.7/204 Parkinson and Smith
(1994); Wolffe et al.
(1998); Frischknecht et
al. (1999); van Eijl et al.
(2000)
A36R VAC (221 aa) 94.6/204
A37R CPV (223 aa) 95.1/204








CPV-GRI isologs Identityd ReferencesStart Stop
A39R 145,363 146,169 268 A40R VAR (68 aa) 89.6/67
A37R VAC (263 aa) 96.2/262
A38R CPV (268 aa) 95.9/268




A41L VAR (277 aa) 95.7/277 Parkinson et al. (1995);
Sanderson et al. (1996)A38L VAC (277 aa) 96.0/277
A40L CPV (277 aa) 99.3/277
A41L 148,646 147,981 221 E–L Secreted protein reduces
influx of inflammatory cells
A46L VAR (218 aa) 91.4/222 Ng et al. (2001)
A41L VAC (219 aa) 94.1/222
A43L CPV (219 aa) 94.1/222
A42R 148,842 149,243 133 L Profilin-like A47R VAR (133 aa) 99.2/133 Goebel et al. (1990);
Blasco et al. (1991)A42R VAC (133 aa) 97.7/133
A44L CPV (133 aa) 100/133
A43R 149,281 149,874 197 E–L Membrane glycoprotein A48R VAR (195 aa) 92.9/196 Duncan and Smith (1992)
A43R VAC (194 aa) 92.9/197
A45R CPV (196 aa) 94.4/197
A44R 149,894 150,118 74 — VAR —
— VAC —
A46R CPV (78 aa) 95.9/73
A45L 151,252 150,212 346 E 3--Hydroxy-delta5-steroid
dehydrogenase
A49L VAR (210 aa) 94.9/197 Moore and Smith (1992)
A50L VAR (61 aa) 88.1/59
A44L VAC (346 aa) 98.3/346
A47L CPV (346 aa) 98.8/346
A46R 151,299 151,676 125 L Superoxide dismutase-like,
virion core protein
A51R VAR (125 aa) 96.8/125 Goebel et al. (1990);
Almazan et al. (2001)A45R VAC (125 aa) 96.0/125
A48R CPV (125 aa) 98.4/125
A47R 151,666 152,388 240 A52R VAR (240 aa) 95.8/240
A46R VAC (214 aaa) 90.6/203
A49R CPV (240 aa) 96.3/240
A48R 152,404 152,658 84 — VAR —
— VAC —
— CPV —
A49R 153,468 154,082 204 E Thymidylate kinase J2R VAR (205 aa) 98.5/205 Smith et al. (1989a);
Hughes et al. (1991)A48R VAC (204 aa) 99.0/204
A51R CPV (227 aa) 99.0/204
A50R 154,648 156,312 554 E DNA ligase J4R VAR (552 aa) 96.4/554 Kerr and Smith (1989);
Smith et al. (1989b)A50R VAC (552 aa) 97.8/554
A53R CPV (552 aa) 97.8/554
A51R 156,366 157,370 334 J5R VAR (334 aa) 92.2/334
A51R VAC (334 aa) 95.5/334
A54R CPV (334 aa) 96.1/334
B1R 158,318 158,530 70 Kelch-like J8R VAR (172 aa) 77.4/62 Xue and Cooley (1993);
Shchelkunov et al.
(1998)
A55R VAC (564 aa) 86.7/60
A57R CPV (564 aa) 86.7/60
B2R 158,617 159,558 313 E–L EEV membrane glycoprotein
hemagglutinin, prevents
cell fusion
J9R VAR (313 aa) 81.2/319 Shida (1986); Seki et al.
(1990); Brown et al.
(1991)
A56R VAC (315 aa) 93.0/315
A58R CPV (314 aa) 91.7/315
B3R 160,325 161,224 299 E Serine/threonine protein
kinase, essential for DNA
replication, intermediate
transcription factor
B1R VAR (300 aa) 93.6/297 Banham and Smith (1992);
Lin et al. (1992); Rempel
and Traktman (1992);
Kovacs et al. (2001)
B1R VAC (300 aa) 97.0/298
B1R CPV (300 aa) 97.3/298
B4R 161,299 162,810 503 Schlafen-like — VAR — Schwarz et al. (1998);
Shchelkunov et al.
(2000)
B2R VAC (219 aa) 90.7/214
B3R VAC (124 aa) 81.3/123
B2R CPV (503 aa) 89.3/503
B5R 163,058 164,743 561 Ankyrin-like B6R VAR (558 aa) 91.8/562 Shchelkunov et al. (1993b,
1998)B4R VAC (558 aa) 93.1/562









CPV-GRI isologs Identityd ReferencesStart Stop





B7R VAR (317 aa) 93.0/316 Engelstad and Smith
(1992, 1993); Isaacs
et al. (1992); Wolffe
et al. (1993)
B5R VAC (317 aa) 95.9/317
B4R CPV (317 aa) 98.4/317
B7R 165,891 166,421 176 B8R VAR (56 aa) 87.0/46
B6R VAC (173 aa) 87.6/177
B5R CPV (183 aa) 85.8/183
B8R 166,458 167,006 182 — VAR —
B7R VAC (182 aa) 96.7/182
B6R CPV (182 aa) 96.7/182
B9R 167,061 167,864 267 E Secreted IFN- binding
protein
B9R VAR (266 aa) 90.9/263 Alcami and Smith (1995);
Seregin et al. (1996)B8R VAC (272 aa) 97.4/267
B7R CPV (271 aa) 97.3/263
B10R 167,957 168,622 221 Shope fibroma virus T4
protein-like
— VAR — Shchelkunov et al. (1998)
B9R VAC (77 aa) 97.1/69
B8R CPV (221 aa) 97.3/221
B11R 169,744 170,592 282 E Protein kinase-like B12R VAR (134 aa) 77.5/71 Banham and Smith (1993)
B12R VAC (283 aa) 97.2/283
B11R CPV (283 aa) 96.1/283
B12R 170,707 171,741 344 E Serine protease inhibitor-like,
SPI-2, inhibits IL-1
converting enzyme
B13R VAR (344 aa) 93.6/344 Kotwal and Moss (1989);
Ray et al. (1992); Kettle
et al. (1997)
B13R VAC (116 aa) 95.6/114
B14R VAC (222 aa) 90.5/220
B12R CPV (345 aa) 97.1/344
B13R 171,868 172,317 149 VAC B15R B14R VAR (149 aa) 94.6/149
B15R VAC (149 aa) 93.3/149
B13R CPV (149 aa) 94.0/149
B14R 172,403 173,383 326 E Secreted, IL-1 binding,
inhibits virus induced fever




B17R VAR (69 aa) 83.8/68
B16R VAC (290 aa) 95.5/290
B14R CPV (326 aa) 95.4/326
B15L 173,665 173,429 78 B18L VAR (340 aa) 93.3/75
B17L VAC (340 aa) 96.0/75
B15L CPV (340 aa) 95.9/74
B16R 174,203 175,261 352 E Cell surface antigen and
secreted IFN-/-binding
protein
B20R VAR (354 aa) 85.6/353 Ueda et al. (1990); Symons
et al. (1995)B19R VAC (353 aa) 93.8/353
B17R CPV (351 aa) 92.0/351
B17R 175,330 177,711 793 Ankyrin-like B21R VAR (787 aa) 87.9/795 Shchelkunov et al. (1993b,
1998)B20R VAC (127 aa) 95.9/123
B18R CPV (795 aa) 95.9/800
B18R 177,857 178,069 70 Kelch-like — VAR — Shchelkunov et al. (1998)
— VAC —
B19R CPV (557 aa) 90.9/55
B19R 178,963 180,036 357 E Serine protease inhibitor-like,
SPI-1, apoptosis inhibition
B25R VAR (372 aa) 93.0/357 Kotwal and Moss (1989);
Smith et al. (1989c)C12L VAC (353 aa) 95.2/357
B20R CPV (375 aa) 93.9/358
B20R 180,215 180,787 190 — VAR —
— VAC —
B21R CPV (190 aa) 96.3/190
B21R 181,046 186,685 1879 E Putative membrane-
associated glycoprotein,
cadherin-like domain




B22R CPV (1933 aa) 92.5/1935
K1R 187,567 187,779 70 Tumor necrosis factor
receptor-like
— VAR — Shchelkunov et al. (1998)
— VAC —
K3R CPV (167 aa) 91.9/62
R1R 188,372 188,689 105 — VAR —
— VAC —
S1R CPV (210 aa) 82.5/103
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ceeded in cloning one of the two complementary, incom-
pletely base-paired hairpin loop strands of MPV-ZAI DNA.
Alignment of this sequence with those of other orthopoxvi-
ruses indicated considerable conservation and suggested
that only the four nucleotides comprising the loop were
missing (Fig. 1). Interestingly, the putative telomere resolu-
tion sequence of MPV (Fig. 1) is identical to that of VAC and
VAR (Merchlinsky, 1990). The region of tandem repeats
adjacent to the terminal hairpin is rather short in the MPV-
ZAI genome and comprises NR I (85 bp) and NR II (322 bp),
separated by two 70-bp repeats, one element of 70 bp, and
two elements of 54 bp, located between NR II and the ITR
coding sequence (Fig. 2). The organization of this region of
MPV-ZAI DNA is most similar to that of VAR-GAR (Fig. 2).
However, the terminal regions of all the VAR strains have
very short ITRs that lack ORFs and the sets of repeats at the
right and left termini differ (Fig. 2) (Massung et al., 1995).
Coding region
Computer-assisted analysis identified the 190 open
reading frames (ORFs) containing 60 amino acid resi-
dues listed in Table 1. The corresponding ORFs of VAR-
IND, VAC-COP, and CPV-GRI are indicated along with
their predicted amino acid lengths. Four ORFs at the left
side of the MPV-ZAI genome (Fig. 3A) are located within
the ITR and thus have counterparts on the right side of
the genome (Fig. 3B). As expected, all genes known to be
essential in other orthopoxviruses are present in MPV
and occupy the central region of the genome (ORFs C10L
to A25R). These ORFs have greater than 90% sequence
identity with those of other orthopoxviruses. The majority
of species- and strain-specific differences between or-
thopoxviruses reside in the left and right terminal re-
gions, as can also be seen for MPV-ZAI (Figs. 3A and 3B).
MPV-ZAI has no unique genes. On the contrary, MPV-ZAI
is missing 25 ORFs that are found in CPV-GRI (Shchel-
kunov et al., 1998) and 19 potential ORFs calculated for
VAR-IND (Shchelkunov et al., 1993d). While the roles for
some of these genes remain entirely unknown, they
include many that are probably involved in immune eva-
sion, host range, and cell proliferation (Alcami and Kos-







CPV-GRI isologs Identityd ReferencesStart Stop
N1R 188,894 189,355 153 VAC B15R-like — VAR —
B22R VAC (181 aa) 91.5/153
H1R CPV (153 aa) 92.8/153
N2R 189,703 189,924 73 C-terminal part of CPV C3L — VAR —
— VAC —
— CPV —
N3R 190,103 190,633 176 CPV C2L — VAR —
— VAC —
— CPV —
N4R* 190,749 192,062 437 CPV C1L, ankyrin-like — VAR —
— VAC —
— CPV —
J1R* 192,219 193,982 587 Ankyrin-like G1R VAR (585 aa) 89.4/584 Shchelkunov et al. (1993b)
B25R VAC (259 aa) 83.2/232
B26R VAC (103 aa) 69.6/115
B27R VAC (113 aa) 96.9/97
H3R CPV (586 aa) 96.6/586
J2R* 194,073 195,119 348 E Secreted TNF-binding protein G2R VAR (349 aa) 85.1/349 Upton et al. (1991);
Shchelkunov et al.
(1993a); Hu et al. (1994)
B28R VAC (122 aa) 83.5/91
H4R CPV (351 aa) 90.3/351
J3R* 195,248 195,988 246 E–L Secreted CC-chemokine-
binding protein
G3R VAR (253 aa) 83.5/254 Graham et al. (1997);
Smith et al. (1997)B29R VAC (244 aa) 86.4/242
H5R CPV (255 aa) 86.7/255
Note. A dash indicates a deletion in the coding sequence of one virus relative to the other. An asterisk denotes ORFs from the inverted terminal
repeats of the viral genome. IV, IMV, IEV, CEV, and EEV are immature virion, intracellular mature virion, intracellular enveloped virion, cell-associated
extracellular enveloped virion, and extracellular enveloped virion, respectively.
a Number of deduced amino acids (aa) encoded within an ORF.
b Expression time of the corresponding VAC genes revealed experimentally is presented. E, early; E–L, early–late; I, intermediate; L, late. Putative
expression time presupposed from sequence data is in parentheses.
c Experimentally revealed functions of viral proteins or homologies based on searching of PIR and SWISS-PROT databases.
d Values of amino acid sequence identity (in percent) are presented and calculated by FASTA analysis (Pearson and Lipman, 1988) for overlapping
regions of homologous ORFs.
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compared the genes in these categories from MPV and
VAR (Shchelkunov et al., 2001), but we have added the
growth factor and immune evasion genes of VAC and
CPV in Table 2 because the latter contains all such
known to be present in orthopoxviruses. Based on the
number of intact and not extensively truncated virulence
genes (indicated in parentheses), we obtain the follow-
ing: CPV-GRI (17)  VAR-IND (11)  VAR-GAR (11) 
MPV-ZAI (10)  VAC-COP (9)  VAC-MVA (6). MPV-ZAI
also contains fewer ankyrin repeat genes than CPV, as
previously noted (Shchelkunov et al., 2001).
CPV-GRI encodes six 500 amino acid proteins of
unknown function with 22–26% identity to each other that
belong to the kelch superfamily (Kumar et al., 1993;
Shchelkunov et al., 1998). Although VAC-COP encodes
three full-size kelch-like proteins, which are homologous
to the corresponding CPV-GRI proteins (99.4, 97.9, and
98.6% identity, respectively), the MPV-ZAI genome en-
codes only one (C9L) with 97.3% identity to CPV-GRI
protein G3L. In the genome of VARs, these ORFs all
appear to be disrupted, indicating that they are nones-
sential for replication.
FIG. 3. Graphic alignment of the ORFs within the left (A) and right (B) terminal variable genomic region of MPV with corresponding genome
segments of other orthopoxviruses. The sizes and directions of ORFs are marked with arrows. Deletions within the DNA and proteins of one virus
relative to another, exceeding 150 bp and 50 amino acids, respectively, are marked with dots. The black blocks mark the sequences within the ITR
regions. Nucleotide numbers are shown on the right.
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VAC contains two ORFs with phospholipase D mo-
tifs: F13L is necessary for the formation of extracellu-
lar virus and efficient cell-to-cell spread of infection,
whereas K4L is dispensable for replication in tissue
culture (Blasco and Moss, 1991; Cao et al., 1997; Sung
et al., 1997). CPV contains both of these ORFs as well
as an additional putative lipid metabolizing enzyme
that is homologous to lysophospholipase, which is
mutated in VAC strains (Antoine et al., 1998). MPV-ZAI
contains intact versions of these three ORFs (C4L,
C5L, and C19L, Table 1), whereas VAR strains lack C4L
and C5L homologs as a result of deletion of a DNA
segment (Fig. 3A). The functions of the C4L and C5L
proteins are not yet known, although both are encoded
by the two orthopoxviruses, MPV and CPV, with rela-




Based on the DNA sequences of the terminal variable
regions, we considered that the organization of CPV
most closely resembles that of the ancestral orthopoxvi-
rus species and that VAR was slightly more distant from
MPV than from VAC (Shchelkunov et al., 2001). By ana-
lyzing the left and right variable regions separately, how-
ever, the situation appears more complex. The VAC
strains appear closer to MPV-ZAI with respect to their left
FIG. 3—Continued
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terminal variable region and to VAR strains with respect
to the right terminal variable region (Fig. 4). This discrep-
ancy may be due to a complex recombinational origin of
VAC, as suggested by others (Bedson and Dumbell, 1964;
Marennikova and Shchelkunov, 1998).
Concluding remarks
In summary, the genome of MPV appears to be typical
of orthopoxviruses, including a central conserved region,
more variable left and right end regions, and an ITR with
tandem repeats. Comparative analysis of the MPV, VAR,
CPV, and VAC genomes confirmed that MPV is a discrete
species exhibiting multiple differences from other or-
thopoxviruses pathogenic for humans. It seems likely
that the orthopoxviruses analyzed thus far evolved inde-
pendently from a cowpox-like ancestor virus, although





The genome sequence of MPV-ZAI was determined as
described (Shchelkunov et al., 2001) and deposited with
GenBank under Accession No. AF380138. Sequences
were analyzed using software developed at the State
Research Center for Virology and Biotechnology “Vector,”
Koltsovo, Russia (Resenchuk and Blinov, 1995). Protein
homology searches were carried out by BLAST analyses
(Altschul et al., 1997) using NCBI internet resources.
Sequences alignments were prepared using Clustal W
(Thompson et al., 1994). Phylogenies were calculated
with the neighbor-joining (NJ) method (Saitou and Nei,
1987) using the MEGA package of software (Kumar et al.,
1993). For this analysis we used the 47.5-kb right-terminal
and 50.3-kb left-terminal genomic fragments of MPV-ZAI
and the corresponding DNA fragments of VAR-IND, VAR-
BSH, VAR-GAR, VAC-COP, VAC-MVA, and CPV-GRI. The
reliability of the phylogenetic relationship was statisti-
cally evaluated from 1000 bootstrap replicates.
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